Chugai and Taisho Toyama launch treatment of osteoporosis
Aug 30, 2013 (MarketLine via COMTEX) --
Chugai Pharmaceutical Co., Ltd., a Japan-based pharmaceutical company and Taisho Toyama Pharmaceutical Co., Ltd., a Japan-based pharmaceutical company, have launched the ibandronate sodium hydrate, a bisphosphonate antiresorptive agent, for the indication of osteoporosis.
"Bonviva IV Injection" received a manufacturing and marketing approval on June 28, 2013.
A Phase II/III, randomized, double-blind, parallel-group study using sodium risedronate hydrate as a control (MOVER Study: MOnthly intraVenous ibandronatE versus daily oral Risedronate) and other studies showed that "Bonviva IV Injection" was not inferior to existing bisphosphonates in increasing bone mass and reducing the risk of bone fractures when administered once a month.
The safety profile was consistent with the previous overseas study results, and "Bonviva IV Injection" was well tolerated in osteoporotic Japanese patients, the company reported.
Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall
not be liable for errors or delays in the content, or for any actions
taken in reliance thereon
[ Back To Technology News's Homepage ]